Frontlight ResearchEarly access
CompletedEarly phase 1
Effect and Mechanism of Jiajian Guishen Formulation on Premature Ovarian Insufficiency Based on Metabolomics
Key facts
- Who runs it
- Shi Yun
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Early phase 1
- People taking part
- 46 people enrolled
- Started
- 24 Jul 2023
- Ended
- 20 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Jiajian Guishen Formulation
- Record updated
- 5 December 2024
Who can take part
- Age
- 18 years to 39 years
- Sex
- Women only
- Healthy volunteers
- Can take part
Show the full registry criteria (18)Hide the full registry criteria
Who can take part
- POI Inclusion Criteria:
- Patients diagnosed by Western medicine with premature ovarian insufficiency
- Patients with Chinese medicine differentiation of kidney deficiency and liver depression
- 18 ≤ patients' age ≤ 39 years
- Patients who do not use other drugs during treatment
- Patients who voluntarily participate in this study, sign an informed consent form, and agree to take the corresponding treatment plan; The above five items must be met to be included in the POI patient group in this study; Healthy subjects inclusion criteria:
- 18 ≤ Age≤ 39 years old
- menstrual regularity
- There is no abnormality in sex hormone and AMH examination
- Voluntarily participate in this research and sign the informed consent form
- Those who match the general information such as age, height, and weight of the patients included in POI
Who cannot take part
- POI patients with acquired organic lesions or ovarian surgery
- Patients who have taken Western medicine artificial cycle therapy or other endocrine therapy in the past three months
- Patients who are allergic to the drugs used in this study or have a history of previous allergy to traditional Chinese medicines; Those who met any of the above 5 criteria were excluded from this study. Healthy subjects were excluded as (1), (3), (4), (5)
- Patients with serious primary diseases and mental disorders such as cardiovascular and cerebrovascular, liver, kidney and hematopoietic system
- POI exclusion criteria:
- Patients with congenital gonadal dysplasia or a family history similar to "early menopause"
- Patients who are breastfeeding or pregnant
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
1. Identify differential metabolites in POI patients. 2. Analysis of differential metabolites and their involved mechanism pathways.
The 2 groups in the trial
- treatment group(Jiajian Guishen Formulation)Treatment being tested
Jiajian Guishen Formulation is a traditional Chinese medicine, it will be used in POI patients for three menstrual cycles; their blood samples are collected before and after treatment.
Treatment: Jiajian Guishen Formulation
- no-treatment control groupNo study treatment, for comparison
healthy people
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect and Mechanism of Jiajian Guishen Formulation on Premature Ovarian Insufficiency
- Record updated
- 5 December 2024